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Abstract: Systemic sclerosis (SSc) is a connective disease characterized by features of 
autoimmunity, vasculopathy, inﬂ  ammation, and ﬁ  brosis. The disease typically starts with 
Raynaud’s phenomenon, followed by skin thickening in the extremities due to inﬂ  ammation and 
ﬁ  brosis. Fibrosis results from excessive collagen production by ﬁ  broblasts, which constitutes 
the ﬁ  nal common pathway of complex cellular interactions including B cells. Several studies 
have indicated that B cells may play a role in SSc. Lesional skin inﬁ  ltrates from SSc patients 
consist of a variety of cells, including eosinophils, neutrophils, lymphocytes, plasma cells, and 
macrophages. Autoantibodies of several speciﬁ  cities are present in the serum of SSc patients of 
which antitopoisomerase 1 is the most common, and evidence has been gathered for a potential 
pathogenic role of some autoantibodies, eg, anti-PDGF antibodies. The blood of SSc patients 
contains an increased proportion of naïve B cells but a decreased proportion of memory B cells. 
Furthermore, serum levels of interleukin-6, an important pro-inﬂ  ammatory cytokine, have been 
shown to correlate with skin ﬁ  brosis. Animal models of SSc have provided more in-depth 
information on the role of B lymphocytes, eg, through disruption of B cell function. In this 
review we will discuss the evidence that B cells are involved in the pathogenesis of SSc.
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Introduction
Systemic sclerosis (SSc) is a systemic autoimmune, connective tissue disease 
characterized by inﬂ  ammation, vascular endothelial dysfunction, speciﬁ  c immunologic 
abnormalities, and tissue ﬁ  brosis due to an imbalance between collagen production 
and degradation. Although its phenotypic characteristics are heterogeneous and 
disease course variable, two different clinical subtypes can be identiﬁ  ed, the limited 
cutaneous form (lSSc) and the diffuse cutaneous form of SSc (dSSc). The lSSc subset 
is characterized by skin thickening of the face, neck, and distal aspects of the limbs, by 
ischemic digital loss, and an increased prevalence of isolated pulmonary hypertension. 
The dSSc subset involves skin of the proximal limbs as well and affects visceral 
organs, including the lung, heart, gastrointestinal tract, and kidneys, especially at late 
stages. The prevalence of SSc in females is higher than in males and in blacks than 
in whites (Mayes et al 2003). The average age at diagnosis is lower for blacks than 
for whites, and blacks have about a twice higher chance to develop dSSc. A positive 
family history is the strongest risk factor for SSc, although the absolute risk for each 
family member remains low (Arnett et al 2001).
SSc is believed to be caused by the interaction of genetic and environmental factors 
(Jimenez and Derk 2004; Abraham and Varga 2005; Denton and Black 2005), leading 
to a loss of immune tolerance. T and B lymphocytes are responsible for the establish-
ment and maintenance of tolerance as illustrated by the observation that alterations 
in B cell signaling result in autoimmunity. B cell signaling is modulated by response 
regulators, such as CD19 (Goodnow 1996; Conrad et al 2007). For example, combined 
binding of CD19 with the antigen-receptor of B lymphocytes decreases the antigen 
receptor-stimulation threshold a 100-fold (Carter and Fearon 1992). CD19 can also Biologics: Targets & Therapy 2008:2(3) 390
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form a complex with CD21, the receptor for fragments of 
the third complement component (C3), which ampliﬁ  es the 
BCR-signal. This binding of C3 to the CD19–CD21 complex 
links innate with humoral immunity (Tedder et al 1997). 
CD22 is a negative regulator of the BCR complex, termi-
nating signal transduction (Asano et al 2004). Both CD19 
and CD22 have their own regulatory network for the BCR 
complex; CD19 expression causes CD22 phosphorylation, 
while CD22 expression is responsible for the inhibition of 
CD19 (Fujimoto et al 1999; Fujimoto and Sato 2007). This 
CD19/CD22 loop suggests a regulation-balance of autoim-
munity in B cells. In keeping with this, transgenic mice 
overexpressing CD19 showed increased serum levels of 
autoantibodies, indicating that CD19 overexpression disrupts 
tolerance in B cells (Inaoki et al 1997). Interestingly, CD22 
deﬁ  cient mice also had increased levels of autoantibodies 
indicating that CD22 deﬁ  ciency alone is sufﬁ  cient to induce 
autoimmunity (O’Keefe et al 1999).
Whatever the precise abnormal immunological mecha-
nism underlying SSc, the aforementioned studies do illustrate 
how subtle B cell abnormalities lead to survival and activa-
tion of self-reactive B cells, production of autoantibodies and 
autoimmune disease (Lipsky 2001; Youinou 2007).
Pathological features of SSc
Dermal ﬁ  brosis typically starts in the extremities with an 
inﬂ  ammatory phase characterized by mononuclear inﬁ  ltration 
(Fleischmajer et al 1983), which will then progress to ﬁ  brosis. 
Although the exact process is not known, it is suggested that 
as inﬂ  ammation subsides, ﬁ  brosis increases (Sakkas 2005). In 
the skin, thickening of the dermis is found showing accumu-
lation of dense collagen, whereas in the lower dermis small 
vessels showed ﬁ  brous thickening (Fleischmajer et al 1977; 
Jiminez and Derk 2004). An early study on skin biopsies, 
using hematoxylin and eosin (H&E) stainings, showed cel-
lular inﬁ  ltrates consisting of lymphocytes, plasma cells, and 
macrophages in 49% of 65 SSc patients (Fleischmajer et al 
1977). Hussein and colleagues (2005) conﬁ  rmed the pres-
ence of increased numbers of histiocytes, eosinophils, and 
neutrophils in lesional skin of patients with SSc compared 
with the normal skin of healthy controls using H&E stain-
ings. Of note, immunohistochemical (IHC) analysis showed 
no CD20+ B cells in these patients. A recent study, however, 
did show CD20+ B cells in 3 skin biopsies from 8 control SSc 
patients, although in the skin biopsies from 4 SSc patients 
treated with anti-CD20 monoclonal antibody no CD20+ 
B cells were detected. CD3+ T cells were found in all tissue 
samples (Bosello et al 2007). In our own hands abundant 
expression of CD79a+ B cells can be detected in the dermis 
of SSc patients (Figure 1). A mononuclear inﬁ  ltrate was also 
detected by others using IHC in pulmonary tissue samples 
from SSc patients with interstitial lung disease (ILD) show-
ing the presence of CD20+ B cells, CD3+ T cells, and CD68+ 
macrophages (Lafyatis et al 2007). Plasma cells were not 
stained in this study. A gene expression study on SSc skin 
samples provided further evidence for a prominent role of 
B cells (Whitﬁ  eld et al 2003). Gene clusters involving groups 
of genes characteristically expressed in endothelial cells, 
B lymphocytes, those associated with synthesis of extracel-
lular matrix, and genes expressed in T cells were highly 
expressed in tissue from the SSc patients when compared to 
healthy controls. Gene expression from skin biopsies showed 
prominent gene expression (immunoglobulins and CD53 
genes) associated with B-lymphocytes, including plasma 
cells, indicating that the mononuclear cell inﬁ  ltrates consist 
of a variety of cells.
Autoantibodies in SSc
Autoantibodies are present in 95% of SSc patients, and are 
either speciﬁ  c for SSc or have overlap with other connective 
diseases (Meyer 2006). The autoantibodies antitopoisomer-
ase 1 (anti-Topo 1, Scl-70), anti-RNA polymerase III, and 
anti-U3 RNP are associated with dSSc, whereas others, like 
anticentromere, anti-U1 RNP, anti-PmScl, and anti-Th/To 
are associated with lSSc. The incidence rates of these auto-
antibodies vary among different ethnic groups (Kuwana 
et al 1999; Reveille et al 2001). In a study of 1,432 cases 
from the Pittsburgh Scleroderma Databank, 10-year survival 
was linked to autoantibody status. In patients with lSSC the 
10-year survival was 75% in patients positive for anticen-
tromere antibody, 88% for those with anti-U1 RNP, 72% in 
those with anti-PmScl, and 65% in patients with anti-Th/To 
autoantibodies. For dSSC patients the 10-year survival was 
64% for patients with anti-Topo 1, 75% for patients with 
anti-RNA polymerase III, and 61% in those with anti-U3 
RNP autoantibodies (Steen 2005). Different autoantibodies 
are associated with different clinical manifestations. ILD 
is associated with anti-Topo 1, pulmonary hypertension 
with anticentromere antibodies, anti-3U RNP, and anti-
Th/To, whereas renal hypertension is associated with RNA 
polymerase III antibodies (Meyer 2006).
Anti-Topo1 is the most common autoantibody (10%–30%) 
in dSSc (Tan et al 1988; Kuwana et al 1994). Its serum levels 
correlate positively with disease activity and disease severity 
in SSc (Hu 2003). Moreover, loss of anti-Topo 1 has been 
associated with clinical improvement (Kuwana et al 2000).Biologics: Targets & Therapy 2008:2(3) 391
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More recently, other autoantibodies have been detected 
in the sera of SSc patients (Arnett 2006). These include 
antiendothelial cell antibodies (AECAs), antiﬁ  brillin-1 (anti-
FBN1) antibodies, antibodies against matrix metalloprotein-
ases (MMP), and antiplatelet-derived growth factor receptor 
(PDGFR) antibodies. Some of the AECAs have been shown 
to bind to the human cytomegalovirus late protein UL94, and 
induce endothelial cell apoptosis via the interaction with the 
cell surface integrin-NAG-2 protein complex (Lunardi et al 
2000). Anti-FBN1 antibodies activate normal ﬁ  broblasts 
resulting in the increased production of ECM components 
(Zhou et al 2005). Anti-PDGFR autoantibodies induce 
Figure 1 CD79a+ B cell inﬁ  ltrate in dermis of patient with systemic sclerosis (parafﬁ  n section, 100x magniﬁ  cation upper ﬁ  gure, 200x magniﬁ  cation lower ﬁ  gure).Biologics: Targets & Therapy 2008:2(3) 392
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collagen 1 production by reactive oxygen species cascades, 
and convert resting ﬁ  broblasts into myoﬁ  broblasts (Baroni 
et al 2006). Further autoantibodies found in SSc patients 
include antiﬁ  broblast antibodies (AFA), which are capable 
of binding to the surface of ﬁ  broblasts (Chizzolini et al 
2002), and autoantibodies against the molecular chaperone 
heat-shock protein 47 (HSP47) (Fujimoto et al 2004). The 
presence of circulating, potentially functional, autoantibodies 
argues in favor of a pathogenic role of B cells in SSc.
Other immunological abnormalities 
in SSc
B cells, among other cells, secrete interleukin-6 (IL-6), 
which stimulates ﬁ  broblasts to produce collagen. In a mouse 
scleroderma model, B cell depletion using an anti-mouse 
CD20 monoclonal antibody led to a decrease in IL-6 mRNA 
levels and a reduction of ﬁ  brosis (Hasegawa et al 2006). 
IL-6 serum levels and spontaneous IL-6 production by 
peripheral blood mononuclear cells (PBMCs) are higher in 
SSc patients compared with normal controls. In addition, it 
was shown that IL-6 serum levels correlate with skin ﬁ  brosis 
(Sato et al 2001). Thus, IL-6 may be an important target for 
the treatment of SSc in humans. Other cytokines may also 
be involved. In SSc patients elevated levels of IL-4, IL-8, 
IL-10, IL-12, IL-13, and IL-17 were found, suggesting that 
both B and T cells are involved in the pathogenesis of SSc 
(Hasegawa et al 1997; Kurasawa et al 2000; Sato et al 2000a; 
Furuse et al 2003). The CD4+ T helper cells 2 (Th2) cytokines 
IL-4, IL-6, and IL-13 stimulate the synthesis of collagen by 
ﬁ  broblasts, leading to excessive scar formation and ﬁ  brosis 
(Duncan and Berman 1991; Wynn 2004). One of the key 
cytokines involved in tissue ﬁ  brosis is transforming growth 
factor-β (TGF-β) (Varga and Abraham 2007). Human B lym-
phocytes, amongst other cells, can be a source of TGF-β and 
express receptors for TGF-β (Kerhl et al 1986). TGF-β pro-
motes collagen deposition and inhibits collagen degradation 
by decreasing MMPs and increasing the tissue inhibitors 
of metalloproteinases (TIMP) expression (Verrecchia et al 
2007). Serum TIMP-1, but not MMP-1 levels, are elevated 
in SSc patients compared with normal controls, indicating 
that collagen accumulation results from inhibition rather than 
a decrease in MMPs (Young-Min et al 2001).
Flowcytometric analysis of peripheral blood mono-
nuclear cells from SSc patients showed an increased num-
ber of naïve B cells, but a decreased number of memory B 
cells and plasmablasts (Sato et al 2004). CD19 expression 
was increased in both naïve and memory B cells, but only 
memory B cells had an activated phenotype with increased 
expression of CD80, CD86, and CD95 suggesting chronic 
activation. Another study showed a 20% higher CD19 and 
CD21 cell surface density in blood samples from SSc patients 
compared with normal controls, but similar expression levels 
of CD20, CD22, and CD40 (Sato et al 2000b). SSc patients 
have elevated levels of B lymphocyte stimulator (BAFF) 
(Matsushita et al 2006). SSc B cells showed increased levels 
of BAFF receptor (BAFFR) as well, indicating a pathogenic 
role of B cells caused by BAFF. BAFF combined with BCR 
ligation stimulates B cell activity, and was shown to rescue 
some self-reactive B cells from death (Schneider et al 1999; 
Thien et al 2004). Another role of BAFFR is the upregula-
tion of Bcl-2 expression as well as nuclear factor kappa-B 
(NF-κB) activation, favoring B cell survival (Do et al 2000). 
These studies indicate that BAFF might promote the survival 
of B cells, thereby contributing to autoimmunity in SSc.
Animal models of SSc
There are several mouse models with features of SSc 
(summarized in Table 1). The University of California, Davis 
(UCD) line 200 chickens have numerous immunopathologic 
and serologic features in common with human scleroderma 
(Gershwin et al 1981). As early as 7 days, lymphocytic 
inﬁ  ltration with T and B cells, followed by ﬁ  brosis and 
Table 1 Overview of animal models of scleroderma and comparison with immunological and clinical features of human scleroderma
Human scleroderma GVH SSc in BALB/c mice UCD-200 chickens Bleomycin-induced
scleroderma
TSK/+ mice
Autoantibodies ++ + + +
Vasculopathy  ++ + − +
Fibrosis
 Skin ++ + + +
 Internal ++ + + −
Inﬂ  ammation  ++ + + −
Abbreviations: GVH SSc, graft-versus-host systemic sclerosis; TSK, tight-skin; UCD, University of California, Davis. Biologics: Targets & Therapy 2008:2(3) 393
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vascular occlusion of the skin, feet, and comb can be observed 
(Van de Water et al 1989; Gruschwitz et al 1991) Inﬁ  ltration 
of CD4+ cells precedes that of CD8+ and B cells, but during 
maturation of the skin lesion B cell clusters increase in size, 
and in mature lesions distinct B and T cell areas are recog-
nized. Also antinuclear antibodies, antibodies to collagen and 
rheumatoid factor can be detected in this model, as well as 
antiendothelial cell antibodies (Sgonc et al 1996).
In another model, the injection of bleomycin into the 
skin of mice results in histological dermal changes with 
thickened and homogenous collagen bundles and cellular 
inﬁ  ltrates consisting mainly of CD4+ lymphocytes, mast 
cells and macrophages similar to human scleroderma skin. 
Bleomycin treatment also leads to the production of serum 
autoantibodies (Yamamoto et al 1999; Yamamoto 2006). 
In MRL/lpr mice deﬁ  cient for interferon-gamma (IFN-γ) 
(MRL/lprγR-/-) histological changes are described resem-
bling human scleroderma, such as accumulation of collagen 
and mononuclear cell inﬁ  ltration with T and B cells, and 
macrophages in connective tissue of several organs as well 
as intima thickening (Le Hir et al 1999).
The tight-skin (TSK) mouse is a third model of SSc, 
and although it does not share all its phenotypic character-
istics, autoantibodies are found against SSc-speciﬁ  c target 
autoantigens including Topo I, ﬁ  brillin 1 (Fbn-1), RNA 
polymerase I, collagen type I, and Fcγ receptors (Bona and 
Rothﬁ  eld 1994). It is believed that the TSK phenotype is 
caused by an internal duplication within the ﬁ  brillin 1 gene, 
resulting in a 3 kb larger transcript compared with the wild-
type transcript (Siracusa et al 1996). Mice homozygous for 
this mutation die in utero, while heterozygous (TSK/+) mice 
survive and develop cutaneous ﬁ  brosis, pulmonary emphy-
sema, and cardiac hypertrophy (Saito et al 2000; Fujimoto and 
Sato 2007). The immunological abnormalities are not well 
understood, however. The infusion of bone marrow cells of 
TSK/pa mice into pa/pa littermates resulted in scleroderma-
like skin changes with thickening of the deep dermis and a dif-
fuse, interstitial mononuclear inﬁ  ltrate, consisting of activated 
lymphocytes, plasma cells and activated macrophages three 
months later, preceded by a rise in anti-RNA polymerase 1 and 
Topo 1 autoantibodies (Phelps et al 1993). In another study in 
the TSK/+ mouse model it was shown that CD19 deﬁ  ciency 
resulted in reduction of skin thickness in these mice (Saito 
et al 2002). Due to this deﬁ  ciency, IL-6 production by TSK/+ 
B cells as well as autoantibody production in TSK/+ mice was 
decreased, showing that there is a CD19 dependent signalling 
pathway in B cells contributing to systemic autoimmunity and 
skin sclerosis in TSK/+ mice.
A more recent mouse model has been a modiﬁ  ed model of 
graft-versus-host (GVH)-induced SSc. The injection of spleen 
B cell Fibrosis IL-6
CD22 CD19















Figure 2 Potential pathways through which B cells mediate or contribute to ﬁ  brosis.Biologics: Targets & Therapy 2008:2(3) 394
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cells from B10.D2 mice into BALB/c mice deﬁ  cient in mature 
T and B cells induces a disease resembling SSc with dermal 
thickening, progressive ﬁ  brosis in internal organs, vasculopa-
thy, and presence of autoantibodies (Ruzek et al 2004).
Summary
The ﬁ  ndings from a number of (pre)clinical studies point 
to a potential role for B lymphocytes in the pathogenesis of 
systemic sclerosis. These include abnormal B cell signalling 
in TSK/+ mice, the presence of B cells and expressed B cell 
genes in skin biopsies from SSc patients, abnormalities in 
numbers and activation status of B cells in peripheral blood, 
the presence of serum autoantibodies and elevated serum levels 
of cytokines such as IL-6 which correlate with skin ﬁ  brosis. B 
cells could contribute to ﬁ  brosis through several mechanisms, 
depicted in Figure 2. The stage is set for clinical trials to inves-
tigate whether B cell depletion in SSc is effective as in other 
autoimmune diseases (Looney 2002; Browning 2006; Blank 
and Shoenfeld 2007). Preliminary results from a pilot study in 
SSc patients with rituximab, a chimeric anti-CD20 monoclonal 
antibody are encouraging (Bosello et al 2007).
Nevertheless, our understanding of the precise contribu-
tion of B lymphocytes in the early stages in the pathogenesis 
of systemic sclerosis is limited, and some of the evidence 
circumstantial. Further studies are therefore needed to dissect 
the speciﬁ  c contribution of B lymphocytes in the pathogen-
esis of systemic sclerosis.
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